FOLD Financial Facts

General and administrative: 5.27M
Loss from operations: -16.82M
See Full Income Statement

Cash and cash equivalents: 19.67M
Deficit accumulated during the development stage: -426.23M
See Full Balance Sheet

Amicus Therapeutics, Inc. (FOLD) Earnings

  |   Expand Research on FOLD
Next EPS Date 5/29/15 *Est. EPS Growth Rate -9.1% *Last Qtr.
Average EPS % Beat Rate +2.3% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +1.0% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
3/3/15 Q414 -$0.24-$0.18 -$0.06N/A$390K N/A Details
5/4/11 Q111 -$0.39-$0.35 -$0.04$6M$1.24M N/A Details
2/13/12 Q411 -$0.25-$0.37 +$0.12$922K$6.06M N/A Details
2/14/11 Q410 -$0.48-$0.15 -$0.33$922K$9M N/A Details
11/5/12 Q312 -$0.31-$0.24 -$0.07$5.8M$8.82M N/A Details
5/10/12 Q112 -$0.35-$0.36 +$0.01$7.8M$7.52M N/A Details
3/12/13 Q412 -$0.20-$0.37 +$0.17N/AN/A N/A Details
11/1/11 Q311 -$0.28-$0.33 +$0.05$5.8M$5.07M N/A Details